JPH09504224A - プロセス▲i▼ - Google Patents
プロセス▲i▼Info
- Publication number
- JPH09504224A JPH09504224A JP7510748A JP51074895A JPH09504224A JP H09504224 A JPH09504224 A JP H09504224A JP 7510748 A JP7510748 A JP 7510748A JP 51074895 A JP51074895 A JP 51074895A JP H09504224 A JPH09504224 A JP H09504224A
- Authority
- JP
- Japan
- Prior art keywords
- agglomerates
- screw
- agglomerate
- size
- screw feeder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 239000002245 particle Substances 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 29
- 230000002776 aggregation Effects 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 238000005054 agglomeration Methods 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000012467 final product Substances 0.000 claims abstract description 8
- 239000008188 pellet Substances 0.000 claims abstract description 8
- 238000004513 sizing Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 44
- 238000005563 spheronization Methods 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 18
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 230000004931 aggregating effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229940112141 dry powder inhaler Drugs 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 2
- 239000011295 pitch Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 10
- 239000011164 primary particle Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229960005105 terbutaline sulfate Drugs 0.000 description 4
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000002664 inhalation therapy Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 101100282787 Caenorhabditis elegans gba-1 gene Proteins 0.000 description 1
- 101100282794 Caenorhabditis elegans gba-2 gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/20—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by expressing the material, e.g. through sieves and fragmenting the extruded length
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Control Of Multiple Motors (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Exchange Systems With Centralized Control (AREA)
- Stereophonic System (AREA)
- Glanulating (AREA)
- General Preparation And Processing Of Foods (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mixers Of The Rotary Stirring Type (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.10μm未満の粒径を有し、流動性の悪い微粒粉末状薬剤を処理して易流動性 でありかつ解体して微粒薬剤となることができる凝集塊またはペレットを制御し ながら形成する方法であって、 a) 材料をスクリューフィーダへ送ってそこを通過させることによって10μm 未満の粒径を有する粉末状薬剤を凝集させる段階と、 b) こうしてできた凝集塊を球形化して、スクリューフィーダにおける凝集段 階から得た凝集塊よりも球形度が大きく、稠密度が大きく、よりコンパクトであ る凝集塊を得る段階と、 c) この凝集塊を分粒して最終製品の均一なサイズを得る段階と からなることを特徴とする方法。 2.請求項1記載の方法において、好ましくは1つまたはそれより多くのスクレ ーパを備えた傾斜した粒状化容器を用いて凝集段階から得た凝集塊を球形化する ことを特徴とする方法。 3.請求項1または2記載の方法において、得た凝集塊のふるい分けのためにふ るいを用いることを特徴とする方法。 4.請求項1記載の方法において、微粒粉末状薬剤の粒径が10μm未満であり、 凝集段階後の凝集塊のサイズが2mmより小さいかまたは等しいことを特徴とする 方法。 5.請求項1記載の方法において、微粒粉末状薬剤を、約2−20mm、好ましくは 、5−15mmのスクリュー・ピッチを有する二軸コンケーブ・スクリューからなる スクリューフィーダに供給することを特徴とする方法。 6.請求項1から5のうちいずれか1つの項に記載の方法において、スクリュー フィーダでの凝集後に、さらに、凝集粉末をふるい分けして凝集塊を均一なサイ ズにする段階を包含することを特徴とする方法。 7.請求項6記載の方法において、球形化後、別のふるい分け段階と別の球形化 段階を行うことを特徴とする方法。 8.請求項7記載の方法において、別のふるい分け段階について別のふるいを用 い、球形化のために、好ましくは1つまたはそれより多くのスクレーパを備えた 別の傾斜した粒状化容器を用いることを特徴とする方法。 9.請求項1から8のうちいずれか1つの項に記載の方法において、粒状化容器 の周速が好ましくは0.5〜1.0m/sであることを特徴とする方法。 10.請求項1から9のうちいずれか1つの項に記載の方法において、球形化時間 が好ましくは2〜20分であることを特徴とする方法。 11.10μm未満の粒径を有し、流動性の悪い微粒粉末状薬剤を処理して粉末状薬 剤から易流動性でありかつ解体して微粒薬剤となることができる小さいばらの凝 集塊またはペレットを制御しながら形成する装置であって、少なくとも2つの協 動して回転するスクリュー(8a、8b)を備えたスクリューフィーダ(6、6′) と、得られた凝集塊を球形化する球形化装置と、凝集塊を分粒して最終製品の均 一なサイズを得る分粒装置とからなることを特徴とする装置。 12.請求項11記載の装置において、好ましくは1つまたはそれより多くのスクレ ーパ(18)を備えた傾斜した粒状化容器(16、16′) を用いて凝集段階で得た凝集塊を球形化することを特徴とする装置。 13.請求項11または12記載の装置において、得た凝集塊をふるい分けするために ふるい(20、20′)を用いることを特徴とする装置。 14.請求項11記載の装置において、スクリューフィーダ(6、6′)が約2〜20m m、好ましくは、5〜15mmのスクリュー・ピッチを有する二軸コンケーブ・スク リュー(8a、8b)を包含することを特徴とする装置。 15.請求項11または12記載の装置において、第1の別のふるい(22)と、第2の別 のふるい(24)と、好ましくは1つまたはそれより多くのスクレーパを備えた第 1の別の傾斜した粒状化容器(26)とを包含することを特徴とする装置。 16.請求項11から15のうちいずれか1つの項に記載の装置において、ふるいの孔 が0.2〜2.0mm、好ましくは、0.3〜1.0mmのサイズを有することを特徴とする装置 。 17.請求項1から10のうちいずれか1つに記載の方法を実施するために請求項11 から16のうちいずれか1つに記載の装置の使用。 18.呼吸作動式乾燥粉末吸入器で使用するための請求項11から16に記載の装置を 用いて請求項1から10に記載の方法に従って製造した凝集塊。 凝集塊。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303214-2 | 1993-10-01 | ||
SE9303214A SE9303214D0 (sv) | 1993-10-01 | 1993-10-01 | Process I |
SE9304271-1 | 1993-12-22 | ||
SE9304271A SE9304271D0 (sv) | 1993-12-22 | 1993-12-22 | Process I |
PCT/SE1994/000896 WO1995009615A1 (en) | 1993-10-01 | 1994-09-29 | Process i |
US08/317,033 US5551489A (en) | 1993-10-01 | 1994-10-03 | Agglomeration of finely divided powders |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504224A true JPH09504224A (ja) | 1997-04-28 |
JP3732508B2 JP3732508B2 (ja) | 2006-01-05 |
Family
ID=27355730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51074895A Expired - Lifetime JP3732508B2 (ja) | 1993-10-01 | 1994-09-29 | 粉末状薬剤の製造方法 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5551489A (ja) |
EP (1) | EP0721331B1 (ja) |
JP (1) | JP3732508B2 (ja) |
CN (1) | CN1110300C (ja) |
AT (1) | ATE209903T1 (ja) |
AU (1) | AU679789B2 (ja) |
BR (1) | BR9407686A (ja) |
CZ (1) | CZ289214B6 (ja) |
DE (1) | DE69429357T2 (ja) |
DK (1) | DK0721331T3 (ja) |
EG (1) | EG20677A (ja) |
ES (1) | ES2166786T3 (ja) |
FI (1) | FI116364B (ja) |
HU (1) | HU222355B1 (ja) |
IL (1) | IL111080A (ja) |
NO (1) | NO314836B1 (ja) |
NZ (1) | NZ274277A (ja) |
PL (1) | PL175564B1 (ja) |
PT (1) | PT721331E (ja) |
RU (1) | RU2170082C2 (ja) |
SG (1) | SG48049A1 (ja) |
SK (1) | SK283569B6 (ja) |
WO (1) | WO1995009615A1 (ja) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
SE9700136D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
US5983956A (en) * | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
SE9700134D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
DE19522899C1 (de) * | 1995-06-23 | 1996-12-19 | Hexal Pharmaforschung Gmbh | Verfahren zum kontinuierlichen Ersintern eines Granulats |
US5826633A (en) | 1996-04-26 | 1998-10-27 | Inhale Therapeutic Systems | Powder filling systems, apparatus and methods |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
GB9616047D0 (en) * | 1996-07-31 | 1996-09-11 | Glaxo Group Ltd | Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof |
SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
CA2706634C (en) * | 1997-03-20 | 2012-10-23 | Schering Corporation | Preparation of powder agglomerates |
US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
EP0876814A1 (en) | 1997-05-07 | 1998-11-11 | "PHARLYSE", Société Anonyme | Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it |
US6182712B1 (en) | 1997-07-21 | 2001-02-06 | Inhale Therapeutic Systems | Power filling apparatus and methods for their use |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
AU2081999A (en) * | 1998-01-13 | 1999-08-02 | Astrazeneca Uk Limited | Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
EP1210067A2 (en) * | 1999-08-25 | 2002-06-05 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US7304750B2 (en) | 1999-12-17 | 2007-12-04 | Nektar Therapeutics | Systems and methods for non-destructive mass sensing |
US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
JP2005504715A (ja) * | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 持続放出特性を有する吸入用粒子 |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
US7659404B2 (en) | 2001-02-14 | 2010-02-09 | Tibotec Pharmaceuticals Ltd. | Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors |
PL367084A1 (en) | 2001-04-09 | 2005-02-21 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors |
WO2002092595A1 (en) | 2001-05-11 | 2002-11-21 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors |
US20030129250A1 (en) * | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
PT1455755E (pt) * | 2001-11-20 | 2013-06-18 | Civitas Therapeutics Inc | Composições particuladas melhoradas para distribuição pulmonar |
BR0215260A (pt) | 2001-12-21 | 2004-12-07 | Tibotec Pharm Ltd | Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro |
MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
DE60315984T2 (de) | 2002-05-17 | 2008-05-29 | Tibotec Pharmaceuticals Ltd. | Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung |
CA2493940C (en) | 2002-08-14 | 2011-11-22 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
EP1417958A1 (en) * | 2002-11-08 | 2004-05-12 | Pari GmbH | Wet granulation process |
SG145742A1 (en) | 2003-09-11 | 2008-09-29 | Tibotec Pharm Ltd | Entry inhibitors of the hiv virus |
SE528121C2 (sv) * | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
AR048650A1 (es) | 2004-05-04 | 2006-05-10 | Tibotec Pharm Ltd | Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih |
JP5073480B2 (ja) | 2004-05-07 | 2012-11-14 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
AP2006003791A0 (en) | 2004-05-17 | 2006-10-31 | Tibotec Pharm Ltd | 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones |
RU2377243C2 (ru) | 2004-05-17 | 2009-12-27 | Тиботек Фармасьютикалз Лтд. | 6,7,8,9-ЗАМЕЩЕННЫЕ 1-ФЕНИЛ-1,5-ДИГИДРОПИРИДО (3,2-b) ИНДОЛ-2-ОНЫ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ АНТИИНФЕКЦИОННЫХ ФАРМАЦЕВТИЧЕСКИХ СРЕДСТВ |
MXPA06013315A (es) | 2004-05-17 | 2007-02-02 | Tibotec Pharm Ltd | 1,5-dihidro-pirido[3,2-b]indol-2-onas 4-sustituidas. |
TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
EP1940856B1 (en) | 2005-10-21 | 2014-10-08 | Universiteit Antwerpen | Novel urokinase inhibitors |
WO2007113290A1 (en) | 2006-04-03 | 2007-10-11 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones |
DE102007049931A1 (de) | 2007-10-18 | 2009-04-23 | Pharmatech Gmbh | Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten |
EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
MX2011011122A (es) * | 2009-04-24 | 2011-11-04 | Schering Corp | Formulaciones de aglomerados que incluyen agentes farmaceuticos activos con tamaños de particula objetivo. |
BR112012021889B1 (pt) | 2010-03-02 | 2022-01-11 | Ph Pharma Co., Ltd | Compostos de amidas heterocíclicas e composição que as compreende para a prevenção ou o tratamento de doenças oculares |
US20110224229A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Novel Crystalline Form |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
GB201102237D0 (en) | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
GB201108225D0 (en) | 2011-05-17 | 2011-06-29 | Amakem Nv | Novel KBC inhibitors |
GB201113689D0 (en) | 2011-08-09 | 2011-09-21 | Amakem Nv | Novel PDE4 inhibitors |
GB201114854D0 (en) | 2011-08-29 | 2011-10-12 | Amakem Nv | Novel rock inhibitors |
MX2014002395A (es) | 2011-08-31 | 2014-06-05 | Amakem Nv | Inhibidores de rock suaves, novedosos. |
US9090630B2 (en) | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
JP6082397B2 (ja) | 2011-09-30 | 2017-02-15 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエIpsen Pharma S.A.S. | マクロ環状lrrk2キナーゼ阻害剤 |
EP2810198B1 (en) | 2012-01-30 | 2023-07-12 | Universiteit Gent | Anti-invasive compounds |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
AU2014230125A1 (en) | 2013-03-15 | 2015-10-29 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
WO2015150337A1 (en) | 2014-04-01 | 2015-10-08 | Amakem Nv | Lim kinase inhibitors |
EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
EP3166955B1 (en) | 2014-07-08 | 2018-05-02 | Universiteit Gent | Hamamelitannin analogues and uses thereof |
JP2017529365A (ja) | 2014-09-17 | 2017-10-05 | オンコデザイン エス.ア. | 大環状lrrk2キナーゼ阻害剤 |
CA2958782C (en) | 2014-09-17 | 2024-01-09 | Oncodesign S.A. | Macrocyclic rip2 kinase inhibitors |
WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
WO2016146651A1 (en) | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
WO2017146994A1 (en) * | 2016-02-24 | 2017-08-31 | Merck Sharp & Dohme Corp. | Controlled agglomeration of micronized drug or drug-excipient mixtures |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
WO2018065387A1 (en) | 2016-10-04 | 2018-04-12 | Universiteit Gent | Novel hamamelitannin analogues and uses thereof |
EP3544952B1 (en) | 2016-11-24 | 2024-11-06 | Universiteit Antwerpen | Halogenated benzotropolones as atg4b inhibitors |
WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
PL3621963T3 (pl) | 2017-05-11 | 2024-05-20 | Remynd N.V. | Związki do leczenia epilepsji, zaburzeń neurodegeneracyjnych i innych zaburzeń oun |
US20210145838A1 (en) | 2018-04-05 | 2021-05-20 | Universiteit Hasselt | Selective pde4d inhibitors against demyelinating diseases |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
JP7370032B2 (ja) | 2019-05-14 | 2023-10-27 | スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド | Parr阻害剤としてのキナゾリン―2.4―ジオン誘導体 |
WO2022157381A1 (en) | 2021-01-25 | 2022-07-28 | Universiteit Hasselt | Phloretin for use in the treatment of neurodegenerative and demyelinating diseases |
WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
EP4405357A1 (en) | 2021-09-23 | 2024-07-31 | Katholieke Universiteit Leuven KU Leuven Research & Development | Ribonucleoside analogues against -sars-cov-2 |
WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2609150A (en) * | 1949-11-05 | 1952-09-02 | Union Carbide & Carbon Corp | Mechanical pulverization of refrigerated plastics |
NL258520A (ja) * | 1960-03-25 | 1900-01-01 | ||
GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
US3802822A (en) * | 1972-03-01 | 1974-04-09 | Mars Mineral Corp | Pelletizer |
GB1569611A (en) * | 1976-01-23 | 1980-06-18 | Fisons Ltd | Pelletised or granular medicament formulation |
GB1520247A (en) * | 1974-08-10 | 1978-08-02 | Fisons Ltd | Pelletised medicament formulations |
US4161516A (en) * | 1975-07-25 | 1979-07-17 | Fisons Limited | Composition for treating airway disease |
US4161526A (en) * | 1978-07-20 | 1979-07-17 | Sterling Drug Inc. | Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions |
DE3268533D1 (en) * | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
US4688610A (en) * | 1985-03-19 | 1987-08-25 | Spiral Systems Inc. | Apparatus for dispensing particulate agglomerating solids |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
GB8606762D0 (en) * | 1986-03-19 | 1986-04-23 | Boots Co Plc | Therapeutic agents |
JPS63116732A (ja) * | 1986-11-06 | 1988-05-21 | Fukae Kogyo Kk | 粉粒体処理装置 |
GB8711005D0 (en) * | 1987-05-09 | 1987-06-10 | British Petroleum Co Plc | Chemical process |
ATE94801T1 (de) * | 1990-01-29 | 1993-10-15 | Ciba Geigy Ag | Verfahren und vorrichtung zur dosierung eines feinkoernigen pulvers. |
GB9027018D0 (en) * | 1990-12-12 | 1991-01-30 | Ici Plc | Heterocyclic compounds |
US5394868A (en) * | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
-
1994
- 1994-09-29 PL PL94313765A patent/PL175564B1/pl unknown
- 1994-09-29 EP EP94929076A patent/EP0721331B1/en not_active Expired - Lifetime
- 1994-09-29 WO PCT/SE1994/000896 patent/WO1995009615A1/en active IP Right Grant
- 1994-09-29 JP JP51074895A patent/JP3732508B2/ja not_active Expired - Lifetime
- 1994-09-29 SK SK391-96A patent/SK283569B6/sk not_active IP Right Cessation
- 1994-09-29 EG EG60594A patent/EG20677A/xx active
- 1994-09-29 CZ CZ1996942A patent/CZ289214B6/cs not_active IP Right Cessation
- 1994-09-29 DK DK94929076T patent/DK0721331T3/da active
- 1994-09-29 RU RU96108803/14A patent/RU2170082C2/ru active
- 1994-09-29 PT PT94929076T patent/PT721331E/pt unknown
- 1994-09-29 HU HU9600821A patent/HU222355B1/hu active IP Right Grant
- 1994-09-29 DE DE69429357T patent/DE69429357T2/de not_active Expired - Lifetime
- 1994-09-29 IL IL11108094A patent/IL111080A/xx not_active IP Right Cessation
- 1994-09-29 SG SG1996006659A patent/SG48049A1/en unknown
- 1994-09-29 NZ NZ274277A patent/NZ274277A/en not_active IP Right Cessation
- 1994-09-29 BR BR9407686A patent/BR9407686A/pt not_active IP Right Cessation
- 1994-09-29 AT AT94929076T patent/ATE209903T1/de active
- 1994-09-29 AU AU78261/94A patent/AU679789B2/en not_active Expired
- 1994-09-29 ES ES94929076T patent/ES2166786T3/es not_active Expired - Lifetime
- 1994-09-29 CN CN94193634A patent/CN1110300C/zh not_active Expired - Lifetime
- 1994-10-03 US US08/317,033 patent/US5551489A/en not_active Expired - Lifetime
-
1996
- 1996-03-29 FI FI961430A patent/FI116364B/fi not_active IP Right Cessation
- 1996-03-29 NO NO19961290A patent/NO314836B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3732508B2 (ja) | 粉末状薬剤の製造方法 | |
KR100347497B1 (ko) | 응집체의제조방법및장치 | |
WO1998010751A1 (fr) | Groupe de particules spheriques, son procede de production et produits pharmaceutiques particulaires spheriques constitues desdits groupes de particules | |
CA2172053C (en) | Process (i) for the preparation of powdered medicament | |
CN114917831B (zh) | 一种适用于微细粉末形成球形颗粒簇团的装置及使用方法 | |
SA94150252B1 (ar) | طريقة وجهاز لتكتيل المساحيق | |
IE45261B1 (en) | Disodium cromoglycate pellets or granules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050920 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051013 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091021 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091021 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101021 Year of fee payment: 5 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101021 Year of fee payment: 5 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101021 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111021 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111021 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121021 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131021 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131021 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |